Lundbeck's Migraine Therapy Vyepti: Overcoming The COVID-19 Effect
Northera Suffers Generic Erosion In First Quarter
Executive Summary
Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.
You may also be interested in...
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
MSN’s Novadoz Makes Multiple US Launches
India’s MSN Labs has kicked off the year by launching four recently-approved generics in the US through affiliate Novadoz, including albendazole, droxidopa, deferasirox and pregabalin. The company says it is preparing a “deep pipeline” of launches for the next 10 years.
Pipeline Watch: The Bumper ASCO Edition
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.